{"name":"Rondo Therapeutics","slug":"rondo-therapeutics","ticker":"","exchange":"","domain":"rondo.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE40dXlLVG0wR3h6bnkwOWY3TmdIbTFISnU4cUl5SFo5RERJQ3M4dDZIZS12TjRERDF3Z05pLWp4dndWZmxpLUw5cWtrV3h1M3NSakVNSUdIODN6MlFkTlJHTUlwYmZKS0JneWtpR0xGRnYxTnJFdzNsSXFHb25wbU0?oc=5","date":"2025-12-04","type":"trial","source":"Clinical Trials Arena","summary":"Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours - Clinical Trials Arena","headline":"Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOekZocGJHNzhlcDBrYW1OTC1tbzNsb2VfbVB4UHRQd2JFdm9oQ1FBcmFFTUVNeVBvdHlvSEIxS2JoQU9OalFqTm54M1o5c3k5dmFMXzdpZGtGNHc1MU1CQ0s1Z212d0x3SUE4M1g0T3B2MnpLS01EblZZTmQxcVQ4QzBULU03VFZETGVVZnpJRW1LSW1Rbm1pTTNOQWNPS2ttN3JmVkstRGJJUXhQS3lWLVdidXFWelEtQUNFMjczek52Vks0RWoxNk9Gc29ZR0lCMV9WT01YVG1YMVNqVE5Xal96YUtDeng1QU0waW5NZ0ZfX0JkWF9CblJYcUdzU0FnYnZWMkk2VTg5TlozVTVNXzBxSUQ5enYtNnZyYjNTb0k4dko3S2VNOXVBdTlNUFhkMUFXaXVQV3p2ajNWM0JXZ0JR?oc=5","date":"2025-12-03","type":"trial","source":"Business Wire","summary":"Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors - Business Wire","headline":"Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPZXM2YVZKT1U2UEhtQTk3MFZJSnFYV051RFlGQ2ZFN2VTR2N1ZHBRdjR0U2NTSFRpcS1lM05Mc0w2VWFiTHNoTmt1dWlDR2VpaTZVSEh2ak0yVmtBekdfbnJhcDU0S0ljTEVIWkhUWjdTY2hRTTJXZ2sxMC14RklubHF4VDJTLXdiazJXRHJHNmptOUNVel9fSFVKSERNX0c2cDhnS0FnV04wU3RHTGszTUJJOWR3T3NiVnNHTDJYeDdsczl6dlVuYjQ1WlAxTmlUMW0yZG1KYkhwc0FiYUdMN2VYbUpLY3A4akstQmlLVlg1ZHNpYzc0dU9Ya1U3VENm?oc=5","date":"2024-12-04","type":"deal","source":"Business Wire","summary":"Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors - Business Wire","headline":"Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNWU5DaERaUy00eXVKM0puYlQ1OUZuOTVvZXFFWUtQcFFJZ2NuNy15bGNndi1HS2ZVcnpQaE1jMjdrdEJGR2c0NjNHVVVqckQ1T2c3ZnJPUjhyb2o0bUNUR3c4LVNhS044UWNBLVpxSXdPZVpCbWRSMkdNUmxWLWlBZGdsUGNRNUcxSW82MmNrLVRMRFhrcVJ1dWRhd1JFRXhObm9fYkJobDlBT2dBaldiZC1mQUg5cGNpdXhTeGRXNGNkekpQazk5NnhDMGJybUE1bktNWjJnNEg2V3FNSzNrdjFzb2ZlVTVZN3lOMjltYkFtM2hFSXhWNlk3SUluYjNlNlM1LTI5dk84QnBTNnhHNUx3LWlvVG8tcTgzZUtOamFlWDdSWWh0dXhrQmtKQQ?oc=5","date":"2024-11-19","type":"pipeline","source":"Business Wire","summary":"Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs - Business Wire","headline":"Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOUZTeUU0X01NSHpqMjc5d0txUVRwZ1dLNHM0Y05jREhMaHBEQ3NiZktwbWhmWldnclQxRzc1bVBUaTBvUG5OOERlTC15WGprQXJmNVpYS0FVaFdYWnFXdTY2M1V2VThMQ2MyNGltUHY0UF9LNmNvQlRCSWU2NTBqR3ExNE5EVkJnd2hTMjJQYURWY2c4dS1PWHdWQUlOT3NxWE16Zl9kdlk?oc=5","date":"2024-07-20","type":"pipeline","source":"Contract Pharma","summary":"Rondo-Pak to Showcase Quick Branded Sampling Capabilities - Contract Pharma","headline":"Rondo-Pak to Showcase Quick Branded Sampling Capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR280RVdVOEhBZmJUWi1CY0o2NnVQVHJxSWhiR05Va3VIb3d2aFB6RjdSRWM4a2U3clF5NVlfeWZOOUwwVEh5MGM2c0dnQlM5WUtJOUtERFVWOWNQM1ExUUhZS1ZtWWZVRWFjb2UyN05FZ0sydUlXV2U1OU9vRi03c1ZUNU1DdENJaThnUFMwcG9ncE44NGhZbkJOWm0wb0VXc19iRi1zS2Q3eWdQZm40aXlTX3U0ejFZcVJfSUVYcVVPckJnNExaRzlhT3h1ZHNqUmd5TDBUaWVnY1hfNFJ6YlVqcmtqUVdKaWc4?oc=5","date":"2024-07-02","type":"pipeline","source":"Business Wire","summary":"Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics - Business Wire","headline":"Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdm9LUU84Qno0OHRxRDlYYUZwTXQxRDBTb09EUjZtelgxbjI2bjc2c0xrQnM2M08wLTZoZjlNYnNwNjdYbDR5VXc2cHFmcUg0UDdhXzZGeWVHdGdsdHcxQW9MWFFDcGx4cUFEV05NZGczbnc3M1NHUVNtZDkzSjlaamJqaDQtdS13Umk5WWVKempGdnd6UE5FOVZxdDRBVW82RnZ2dFRlWm1IMWNYMFViV1Fn?oc=5","date":"2022-03-03","type":"pipeline","source":"MedCity News","summary":"Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs - MedCity News","headline":"Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPaTlrZzdpR0J2NEVpN204TDQtRGRBd1VKaG9xcDdvOEF1MVBRcU84NkZoVEpqNUoyLXRYMjVlYjBkLWRITWFRTXV0akJwRXAzWDJWSGdUSFl0cEpRbU1idmF1WklQMHNKNmJPYlM5N0hrcmhZcmlDQ0JWSTFNVUhHdjJvTlQtLUtEQnhQZ0lyQjZGUm5ZbDdYNHNqN2NGYjNKU3dfWGlVYW9zUHh0YjRjdVJZUW9GQ0N2MmRsN1YtbzlORC12TTQwM0ZWdDJTWXdJRjZXN3NSbHRiYmg3ZTZLRHlEZTdYSDJIYkZEVURYNmZsVUVzWlliamI1WHpMZEdTdFNHSEFZc3pMUWlB?oc=5","date":"2022-03-02","type":"pipeline","source":"PR Newswire","summary":"Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors - PR Newswire","headline":"Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNREUyV1NxXzZwOXExXzB0SnJvZUUzYUU5Nkx4LU5yd19Gb09iZjY0cFVyaVpzSVpoNTNia2hJeFJrWWlETnRzVnFEcS04S0FIUElLdmdUT1BzWUV6azdYWWM0RTlpVzNVOEtibXBHSEh0cHIzRDJrVFp3MTEwc05FYm54SnVDSk5UaklUZmNPcHhtOGJqdVp5Y2NlTi1iN1dIUmFNald4NUxoNy1mV2c?oc=5","date":"2022-03-02","type":"pipeline","source":"The Business Journals","summary":"East Bay biotech startup lands $67M to target solid tumors - The Business Journals","headline":"East Bay biotech startup lands $67M to target solid tumors","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}